triiodothyronine has been researched along with Eye Diseases in 16 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Eye Diseases: Diseases affecting the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The study consisted of an untreated control group and five treatment groups that received continuous exposure to AP via the drinking water at dosage levels of 0." | 1.31 | A 90-day drinking water toxicity study in rats of the environmental contaminant ammonium perchlorate. ( Baker, WH; Dodd, DE; Hildebrandt, PK; Mattie, DR; Siglin, JC, 2000) |
| "Euthyroid Graves' disease is defined as Graves' ophthalmopathy without hyperthyroidism, and the thyroid-stimulating antibody (TSAb) has been known to be a good marker for diagnosis." | 1.30 | Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease. ( Amino, N; Fujikado, T; Hidaka, Y; Kashiwai, T; Shimaoka, Y; Tada, H; Watanabe, Y; Yagoro, A, 1998) |
| "We examined 13 patients with euthyroid Graves' disease suspected ophthalmologically, by comparing them with 20 patients with untreated Graves' disease and by following them up for 5 to 10 years." | 1.29 | Significance of thyroid stimulating antibody and long term follow up in patients with euthyroid Graves' disease. ( Amino, N; Asahi, K; Hidaka, Y; Iwatani, Y; Kashiwai, T; Tada, H; Tamaki, H, 1995) |
| "The patients had Graves' disease, but no other immune-mediated diseases, had not yet received specific treatment for their ophthalmopathy and were euthyroid during the entire study period." | 1.28 | Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy. ( Koornneef, L; Mourits, MP; Prummel, MF; Van der Gaag, R; Wiersinga, WM, 1992) |
| " Group A patients (n = 31) received either methimazole (40-100 mg daily) or propylthiouracil (400-900 mg daily) combined with T3 daily throughout treatment." | 1.28 | The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine. ( Bromberg, N; Romaldini, JH; Sgarbi, JA; Werner, MC; Werner, RS, 1992) |
| "Thyroidal Graves' disease--past or present--was clinically evident in 99 patients (79%): hyperthyroidism in 3 cases." | 1.27 | Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease. ( Koornneef, L; Smit, T; van der Gaag, R; Wiersinga, WM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (56.25) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kashiwai, T | 2 |
| Tada, H | 2 |
| Asahi, K | 1 |
| Hidaka, Y | 2 |
| Tamaki, H | 1 |
| Iwatani, Y | 1 |
| Amino, N | 2 |
| Watanabe, Y | 1 |
| Shimaoka, Y | 1 |
| Yagoro, A | 1 |
| Fujikado, T | 1 |
| Siglin, JC | 1 |
| Mattie, DR | 1 |
| Dodd, DE | 1 |
| Hildebrandt, PK | 1 |
| Baker, WH | 1 |
| Fells, P | 1 |
| Prummel, MF | 1 |
| Wiersinga, WM | 2 |
| Van der Gaag, R | 2 |
| Mourits, MP | 1 |
| Koornneef, L | 2 |
| Bromberg, N | 1 |
| Romaldini, JH | 1 |
| Werner, RS | 1 |
| Sgarbi, JA | 1 |
| Werner, MC | 1 |
| Gomez, JM | 1 |
| Soler, J | 1 |
| Navarro, MA | 1 |
| Imai, Y | 1 |
| Odajima, R | 1 |
| Shimizu, T | 1 |
| Shishiba, Y | 1 |
| Smit, T | 1 |
| Klein, E | 2 |
| Heinze, HG | 1 |
| Pabst, HW | 1 |
| Klemm, J | 1 |
| Hör, G | 1 |
| Mahaux, JE | 1 |
| Nagel, M | 1 |
| Hollows, FC | 1 |
| Beaumont, P | 1 |
| Schneider, C | 1 |
| Hesch, RD | 1 |
| Horster, FA | 1 |
| Reinwein, D | 1 |
2 reviews available for triiodothyronine and Eye Diseases
| Article | Year |
|---|---|
[Results of the thyroid gland function diagnosis with radioiodine in hyperthyroidism and endocrine ophthalmopathies].
Topics: Exophthalmos; Eye Diseases; Humans; Hyperthyroidism; Iodine Radioisotopes; Protein Binding; Radionuc | 1965 |
Thyroid eye disease and its relationship to the long-acting thyroid stimulator.
Topics: Biological Assay; Conjunctiva; Eye Diseases; Eye Movements; Eyelid Diseases; Female; Glycosaminoglyc | 1969 |
14 other studies available for triiodothyronine and Eye Diseases
| Article | Year |
|---|---|
Significance of thyroid stimulating antibody and long term follow up in patients with euthyroid Graves' disease.
Topics: Adult; Aged; Exophthalmos; Eye Diseases; Female; Graves Disease; Humans; Immunoglobulins, Thyroid-St | 1995 |
Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
Topics: Adolescent; Adult; Eye Diseases; Female; Graves Disease; Humans; Hyperthyroidism; Immunoglobulins, T | 1998 |
A 90-day drinking water toxicity study in rats of the environmental contaminant ammonium perchlorate.
Topics: Animals; Body Weight; Drinking; Eating; Estrus; Eye Diseases; Female; Male; Micronucleus Tests; Orga | 2000 |
Surgical management of dysthyroid eye disease: a review.
Topics: Eye Diseases; Humans; Thyroid Diseases; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 1977 |
Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.
Topics: Adult; Eye Diseases; Female; Graves Disease; Humans; Male; Middle Aged; Predictive Value of Tests; P | 1992 |
The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.
Topics: Adolescent; Adult; Autoantibodies; Drug Therapy, Combination; Eye Diseases; Female; Graves Disease; | 1992 |
Thyroid stimulating antibodies in patients with Graves' ophthalmopathy.
Topics: Adolescent; Adult; Antibodies; Cyclic AMP; Eye Diseases; Female; Graves Disease; Humans; In Vitro Te | 1991 |
Serum hyaluronan concentration determined by radiometric assay in patients with pretibial myxedema and Graves' ophthalmopathy.
Topics: Adult; Autoantibodies; Eye Diseases; Female; Graves Disease; Humans; Hyaluronic Acid; Immunoglobulin | 1990 |
Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease.
Topics: Adult; Aged; Eye Diseases; Female; Graves Disease; Humans; Immunoglobulin G; Immunoglobulins, Thyroi | 1988 |
[l-Triiodothyronine suppression test of the thyroid gland].
Topics: Eye Diseases; Humans; Iodine Radioisotopes; Methods; Pituitary Hormone-Releasing Hormones; Thyroid D | 1967 |
[Basdowian ophthalmic diseases. Pathogenic role of L-triiodothyronine and of LATS. Therapeutic role of L-thyroxine, of d-thyroxine and of corticoids].
Topics: Antithyroid Agents; Betamethasone; Dextrothyroxine; Eye Diseases; Graves Disease; Humans; Hyperthyro | 1967 |
[Treatment of endocrine ophthalmopathy].
Topics: Endocrine System Diseases; Eye Diseases; Glucocorticoids; Humans; Hyperthyroidism; Hypnotics and Sed | 1974 |
[Triiodothyronine hyperthyroidism in endocrine ophthalmopathy].
Topics: Eye Diseases; Humans; Hyperthyroidism; Triiodothyronine | 1972 |
[On drug therapy of endocrine ophthalmopathy].
Topics: Edema; Exophthalmos; Eye Diseases; Eyelids; Humans; Long-Acting Thyroid Stimulator; Prednisone; Thyr | 1967 |